Sign In
Buy RNXT
$0.96
+0.0171 (+1.82%)
At Close: Jul 31, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
08:30am, Monday, 14'th Jul 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
09:07pm, Thursday, 15'th May 2025
RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald K
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
08:31pm, Thursday, 15'th May 2025
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
04:05pm, Thursday, 15'th May 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
08:30am, Wednesday, 14'th May 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
08:30am, Tuesday, 06'th May 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
08:30am, Thursday, 01'st May 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
08:30am, Tuesday, 29'th Apr 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
08:30am, Wednesday, 16'th Apr 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
08:30am, Friday, 04'th Apr 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
08:00am, Friday, 28'th Mar 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
08:00am, Wednesday, 19'th Mar 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializi
